Purchase Order N6311626P0504
- Not listed
- This is a firm fixed-price purchase order awarded by the U.S. Navy Bureau of Medicine and Surgery (BUMED) to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The $89,348 contract is for Illumina's RNA Prep with Enrichment, DNA/RNA Universal Dual Indexes, Respiratory Virus Oligo Panel, and MiSeq reagent kits to support nucleic acid sequencing needs at the Naval Medical Research Center's Biological Defense Research Directorate. This award is part of an...
- This is a firm fixed-price purchase order contract awarded by the U.S. Department of the Navy's Bureau of Medicine and Surgery (BUMED) to Illumina, Inc., a manufacturer of sequencing and array-based genomic analysis products. The contract, valued at $80,858.46, is for the delivery of various Illumina sequencing systems, reagents, and consumables to support nucleic acid sequencing needs at the Naval Medical Research Center's Biological Defense Research Directorate. This award is made under an...
- This is a $41,137.76 firm fixed price purchase order awarded by the U.S. Navy Bureau of Medicine and Surgery (BUMED) to Illumina, Inc., a manufacturer of sequencing and genomic analysis products. The contract is for the delivery of Illumina RNA Prep kits and reagents to support laboratories at the Naval Health Research Center (NHRC) in San Diego, California. The award was made on a sole-source basis under the authority of 10 U.S.C. 2304(c)(1), with deliveries scheduled on four dates between...
- This is a firm fixed-price purchase order awarded by the Bureau of Medicine and Surgery (BUMED), a component of the U.S. Department of the Navy, to Illumina, Inc. for $97,678.20. The award provides Illumina's RNA sequencing products and reagents to support the Naval Health Research Center's (NHRC) laboratory work characterizing biological threats. The contract has a period of performance through December 1, 2021. This award is not associated with a set-aside program. Illumina has previously...
- This is a sole-source federal contract award from the U.S. Navy's Bureau of Medicine and Surgery (BUMED) to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The $76,243.05 firm fixed-price purchase order is for Illumina's RNA Prep with Enrichment kits, IDT for Illumina DNA/RNA UD Indexes, Respiratory Virus Oligo Panel v2, and MiSeq Reagent Kits to support nucleic acid sequencing needs at the Naval Medical Research Center's Biological Defense Research...
- This is a delivery order awarded by the Department of the Navy Bureau of Medicine and Surgery (BUMED) to Illumina, Inc., a manufacturer of genomic sequencing systems and reagents. The $67,493.84 fixed-price contract is for the provision of medical laboratory supplies, specifically reagents and controls for Illumina's MiSeq, iSeq, NextSeq, and NovaSeq6000 sequencing platforms. These instruments are used by the Naval Medical Research Center's Biological Defense Research Directorate to characterize...
- The U.S. Navy's Bureau of Medicine and Surgery awarded a $35,668.98 firm fixed price purchase order to Illumina, Inc. on September 10, 2025, for reagents and supplies supporting the Illumina MiSeq Sequencing System at the Naval Health Research Center in San Diego, California. The contract, which utilizes no set-aside designation, procures three specific laboratory products essential for DNA sequencing operations: Illumina Respiratory Virus Enrichment Kit Set A (3 units), MiSeq Reagent Nano Kit...
- This federal contract award to Illumina, Inc. is a purchase order (PO) for a MiSeq System, a genomic sequencing instrument, valued at $95,931.00. The award was made by the U.S. Navy Bureau of Medicine and Surgery (BUMED) and is not associated with a set-aside program. Illumina, a manufacturer of sequencing and genomic analysis instruments and reagents, has a history of providing these products and related services to various federal agencies, including the National Institutes of Health (NIH),...
- This federal contract award, valued at $89,232.71, was issued by the U.S. Navy Bureau of Medicine and Surgery (BUMED) to Illumina, Inc. Illumina, a manufacturer of genomic sequencing instruments and reagents, is providing health check services for BUMED's MiSeq and NextSeq 500 sequencing systems under this firm fixed price purchase order. The award is not associated with a larger contract vehicle and does not have a set-aside designation. Illumina has previously supported genomic research and...
- This is a $99,835.14 firm fixed price purchase order awarded by the Bureau of Medicine and Surgery (BUMED), a component of the U.S. Department of Defense, to Illumina, Inc. The contract is for the provision of Illumina RNA sequencing products and reagents, including NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, sample preparation kits, sequencing chips, and related consumables and support services. These items will support genomic sequencing and bioinformatics analysis for research and...
The Bureau of Medicine and Surgery (BUMED) awarded a $12,990.38 firm fixed-price purchase order to Illumina, Inc. on November 11, 2025, for specialized molecular biology reagents and diagnostic kits with an ultimate completion date of February 6, 2026. The contract covers a MiSeq Reagent Nano Kit V2 (300-cycles) and an Illumina Respiratory Virus Enrichment Kit Set A, both critical components for next-generation sequencing applications. Performance will take place in San Diego, California, where Illumina maintains its corporate headquarters. This award carries no set-aside designation, reflecting the company's position as a specialized sole-source provider of proprietary sequencing technologies and associated consumables within the federal marketplace. This purchase order supports BUMED's diagnostic and research capabilities, likely enabling enhanced infectious disease detection and characterization across Navy and Marine Corps medical facilities. Illumina is a well-established federal contractor with extensive contracting history across multiple agencies, including a substantial $45 million indefinite delivery/indefinite quantity contract with the U.S. Department of Agriculture. The company specializes in genetic sequencing and genomic analysis platforms that support research, diagnostics, and public health applications throughout the federal government. The relatively modest ceiling value reflects the consumable nature of reagent kits, which are regularly procured to support ongoing laboratory operations at military medical research and treatment facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.0k | 11/10/25 |